Anti-vascular endothelial growth factor for neovascular glaucoma

Abstract

Background-Neovascular glaucoma (NVG) is a potentially blinding secondary glaucoma. It is caused by the formation of abnormal new blood vessels which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) agents are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti-VEGFs for the control of intraocular pressure (IOP) in NVG.

Anti-VEGF Intravitreal Bevacizumab for Radiation-Associated Neovascular Glaucoma

“…[32][33][34] However, a recent review suggests that there is insufficient evidence to recommend anti-VEGF treatment for NVG. 35 Our study is the largest series on anti-VEGF treatment for radiation-associated NVG. However, similar to the other retrospective series, our number of cases is too small to prove efficacy.…”

Anti-VEGF Intravitreal Bevacizumab for Radiation-Associated Neovascular Glaucoma

“…[32][33][34] However, a recent review suggests that there is insufficient evidence to recommend anti-VEGF treatment for NVG. 35 Our study is the largest series on anti-VEGF treatment for radiation-associated NVG. However, similar to the other retrospective series, our number of cases is too small to prove efficacy.…”

Effectiveness and safety of intravitreal aflibercept injection for neovascular glaucoma: A single-center, retrospective, observational study in China

“…A retrospective study by Xia et al [21] of 28 eyes that received anti-VEGF agents reported regression of NVI in all the participants. Simha et al [11] reviewed 4 randomized controlled trials of anti-VEGF agents, including intravitreal ranibizumab, bevacizumab, and aflibercept, for the treatment of NVG. The included trials reported inconclusive results on the IOP-lowering effects of anti-VEGF agents; however, the overall evidence of anti-VEGF agents in NVG treatment was low.…”

“…The included trials reported inconclusive results on the IOP-lowering effects of anti-VEGF agents; however, the overall evidence of anti-VEGF agents in NVG treatment was low. [11] Among the anti-VEGF agents, intravitreal bevacizumab is another anti-VEGF agent widely used in NVG. Sun et al [22] reported a significant reduction in IOP and improved visual acuity 6 to 30 months after intravitreal bevacizumab injection in a prospective, interventional case series of 51 eyes in Chinese patients.…”

Clinical Efficacy of Preoperative and Intraoperative Intravitreal Ranibizumab as Adjuvant Therapy of Ahmed Glaucoma Valve Implantation Combined with Vitrectomy in the Management of Neovascular Glaucoma with Diabetic Vitreous Hemorrhage

“…Preoperative administration of anti-VEGF agents has been shown to induce rapid regression of fragile new vessels in the iris and the anterior chamber angle, thus effectively reducing the occurrence of intraoperative hyphema and increasing surgical success after AGV implantation. On the other hand, it could facilitate the removal of vitreous hemorrhage, thus ensuring the safety of the subsequent multiple surgical procedures [12,21]. The preoperative use of IVR as adjuvant therapy in the management of NVG combined with VH has been described in previous reports.…”

Anti-VEGF Intravitreal Bevacizumab for Radiation-Associated Neovascular Glaucoma

“…[32][33][34] However, a recent review suggests that there is insufficient evidence to recommend anti-VEGF treatment for NVG. 35 Our study is the largest series on anti-VEGF treatment for radiation-associated NVG. However, similar to the other retrospective series, our number of cases is too small to prove efficacy.…”

Effectiveness and safety of intravitreal aflibercept injection for neovascular glaucoma: A single-center, retrospective, observational study in China

“…A retrospective study by Xia et al [21] of 28 eyes that received anti-VEGF agents reported regression of NVI in all the participants. Simha et al [11] reviewed 4 randomized controlled trials of anti-VEGF agents, including intravitreal ranibizumab, bevacizumab, and aflibercept, for the treatment of NVG. The included trials reported inconclusive results on the IOP-lowering effects of anti-VEGF agents; however, the overall evidence of anti-VEGF agents in NVG treatment was low.…”

“…The included trials reported inconclusive results on the IOP-lowering effects of anti-VEGF agents; however, the overall evidence of anti-VEGF agents in NVG treatment was low. [11] Among the anti-VEGF agents, intravitreal bevacizumab is another anti-VEGF agent widely used in NVG. Sun et al [22] reported a significant reduction in IOP and improved visual acuity 6 to 30 months after intravitreal bevacizumab injection in a prospective, interventional case series of 51 eyes in Chinese patients.…”

Clinical Efficacy of Preoperative and Intraoperative Intravitreal Ranibizumab as Adjuvant Therapy of Ahmed Glaucoma Valve Implantation Combined with Vitrectomy in the Management of Neovascular Glaucoma with Diabetic Vitreous Hemorrhage

“…Preoperative administration of anti-VEGF agents has been shown to induce rapid regression of fragile new vessels in the iris and the anterior chamber angle, thus effectively reducing the occurrence of intraoperative hyphema and increasing surgical success after AGV implantation. On the other hand, it could facilitate the removal of vitreous hemorrhage, thus ensuring the safety of the subsequent multiple surgical procedures [12,21]. The preoperative use of IVR as adjuvant therapy in the management of NVG combined with VH has been described in previous reports.…”

Anti-VEGF Intravitreal Bevacizumab for Radiation-Associated Neovascular Glaucoma

“…[32][33][34] However, a recent review suggests that there is insufficient evidence to recommend anti-VEGF treatment for NVG. 35 Our study is the largest series on anti-VEGF treatment for radiation-associated NVG. However, similar to the other retrospective series, our number of cases is too small to prove efficacy.…”

Effectiveness and safety of intravitreal aflibercept injection for neovascular glaucoma: A single-center, retrospective, observational study in China

“…A retrospective study by Xia et al [21] of 28 eyes that received anti-VEGF agents reported regression of NVI in all the participants. Simha et al [11] reviewed 4 randomized controlled trials of anti-VEGF agents, including intravitreal ranibizumab, bevacizumab, and aflibercept, for the treatment of NVG. The included trials reported inconclusive results on the IOP-lowering effects of anti-VEGF agents; however, the overall evidence of anti-VEGF agents in NVG treatment was low.…”

“…The included trials reported inconclusive results on the IOP-lowering effects of anti-VEGF agents; however, the overall evidence of anti-VEGF agents in NVG treatment was low. [11] Among the anti-VEGF agents, intravitreal bevacizumab is another anti-VEGF agent widely used in NVG. Sun et al [22] reported a significant reduction in IOP and improved visual acuity 6 to 30 months after intravitreal bevacizumab injection in a prospective, interventional case series of 51 eyes in Chinese patients.…”

Clinical Efficacy of Preoperative and Intraoperative Intravitreal Ranibizumab as Adjuvant Therapy of Ahmed Glaucoma Valve Implantation Combined with Vitrectomy in the Management of Neovascular Glaucoma with Diabetic Vitreous Hemorrhage

“…Preoperative administration of anti-VEGF agents has been shown to induce rapid regression of fragile new vessels in the iris and the anterior chamber angle, thus effectively reducing the occurrence of intraoperative hyphema and increasing surgical success after AGV implantation. On the other hand, it could facilitate the removal of vitreous hemorrhage, thus ensuring the safety of the subsequent multiple surgical procedures [12,21]. The preoperative use of IVR as adjuvant therapy in the management of NVG combined with VH has been described in previous reports.…”